Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai, Norina Tanaka, Shigeki Ito, Mika Sunakawa-Kii, Yuta Kaito, Toshio Asayama, et al. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental hematology. 2023
Shunsuke Yui, Satoshi Wakita, Yasunobu Nagata, Yasuko Kuribayashi, Toshio Asayama, Yusuke Fujiwara, Masahiro Sakaguchi, Satoshi Yamanaka, Atsushi Marumo, Ikuko Omori, et al. Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study. Asia-Pacific journal of clinical oncology. 2022. 19. 1. 136-148
Yusuke Otsuka, Akihiro Shirakabe, Toshio Asayama, Hirotake Okazaki, Yusaku Shibata, Shota Shigihara, Tomofumi Sawatani, Norio Yokose, Kuniya Asai. Successful Treatment of Thrombocytopenia, Anasarca, Fever, Reticulin Myelofibrosis/Renal Insufficiency, and Organomegaly Syndrome Using Plasma Exchange Followed by Rituximab in the Intensive Care Unit. Journal of medical cases. 2021. 12. 12. 474-480
Yasuko Kuribayashi-Hamada, Mariko Ishibashi, Atsushi Tatsuguchi, Toshio Asayama, Namiko Takada-Okuyama, Asaka Onodera-Kondo, Keiichi Moriya, Takehito Igarashi, Hiroyuki Onose, Sakae Tanosaki, et al. Clinicopathologic characteristics and A20 mutation in primary thyroid lymphoma. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2021. 89. 3. 301-308
Mariko Ishibashi, Mika Sunakawa-Kii, Yuta Kaito, Ryosuke Kinoshita, Toshio Asayama, Yasuko Kuribayashi, Koiti Inokuchi, Rimpei Morita, Hideto Tamura. The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma. Experimental hematology. 2020. 90. 72-79
Mariko Ishibashi, Ryosuke Kinoshita, Koiti Inokuchi, Hiroshi Handa, Makoto Sasaki, Norio Komatsu, Yoichi Imai, Norina Hiroike, Junji Tanaka, Sakae Tanosaki, et al. Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. BLOOD. 2019. 134
石橋 真理子, 田村 秀人, 砂川 実香, 海渡 裕太, 木下 量介, 朝山 敏夫, 守屋 慶一, 猪口 孝一, 高橋 秀実. SLAMF3遺伝子多型rs509749は多発性骨髄腫の増悪化に関連する(The rs509749 genotype of the SLAMF3 gene is associated with multiple myeloma aggravation). 臨床血液. 2018. 59. 9. 1487-1487
朝山 敏夫, 田村 秀人, 石橋 真理子, 木下 量介, 福嶋 善光, 濱名 輝彦, 砂川 実香, 海渡 裕太, 守屋 慶一, 汲田 伸一郎, et al. 多発性骨髄腫におけるFDG-PET/CTによる代謝容量パラメーターの臨床的意義(Clinical significance of metabolic and volumetric parameters of FDG-PET/CT in multiple myeloma). 臨床血液. 2018. 59. 9. 1803-1803
朝山敏夫, 田村秀人, 石橋真理子, 木下量介, 福嶋善光, 濱名輝彦, 汲田伸一郎, 守屋慶一, 猪口孝一. 多発性骨髄腫におけるFDG-PET/CTによる代謝容量パラメーターの臨床的意義. International Journal of Myeloma (Web). 2018. 8. 2. 124-124
Mariko Ishibashi, Hideto Tamura, Toshio Asayama, Yasuko Kuribayashi-Hamada, Asaka Onodera, Keiichi Moriya, Makoto Sasaki, Hiroshi Handa, Yoichi Imai, Norina Tanaka, et al. The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma. BLOOD. 2017. 130
